Quick Answer
Lipocine Inc. reported Revenue (ASC 606) of $500.0 thousand for fiscal year 2022.
Lipocine Inc. Revenue (ASC 606) — Annual History
| Fiscal Year | Revenue (ASC 606) | YoY Change |
|---|---|---|
| 2022 | $500.0K | -96.9% |
| 2021 | $16.14M | — |
Quarterly Revenue (ASC 606)
| Quarter Ending | Revenue (ASC 606) | YoY | QoQ |
|---|---|---|---|
| March 31, 2023 | $55.0K | — | -89.0% |
| June 30, 2022 | $500.0K | — | +809.2% |
| September 30, 2021 | $55.0K | — | — |
- Lipocine Inc. showed a decrease of -96.9% in Revenue (ASC 606) compared to the prior fiscal year.
- Over the 2021–2022 period, Lipocine Inc.’s revenue (asc 606) has declined by 96.9% (from $16.14 million to $500.0 thousand).
- The most recent figure is from Lipocine Inc.’s fiscal year 2022 report (Form 10-K), filed with the SEC on March 10, 2023.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: